Trastuzumab deruxtecan for HER2-low unresectable and or metastatic breast cancer after at least one prior line of chemotherapy

Published on 04 Jun 2024
Last Updated on 13 Sep 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating patients with human epidermal growth factor receptor 2 (HER2)-low unresectable and/or metastatic breast cancer who have received at least one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. The decision was based on the unfavourable cost-effectiveness of T-DXd compared with chemotherapy, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.

Trastuzumab deruxtecan for HER2-low unresectable and or metastatic breast cancer after at least 1 prior line of chemotherapy (Updated Sep 24) [PDF, 226 KB]

PES Trastuzumab Deruxtecan for HER2-low Breast Cancer (Updated 13 Sep 2024) [PDF, 101 KB]